Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 634

1.

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T.

PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.

2.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
3.

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ.

Clin Cancer Res. 2011 Nov 15;17(22):7148-55. doi: 10.1158/1078-0432.CCR-11-1274. Epub 2011 Sep 13.

4.

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.

Mur P, Rodríguez de Lope Á, Díaz-Crespo FJ, Hernández-Iglesias T, Ribalta T, Fiaño C, García JF, Rey JA, Mollejo M, Meléndez B.

J Neurooncol. 2015 May;122(3):441-50. doi: 10.1007/s11060-015-1738-9. Epub 2015 Feb 15.

PMID:
25682093
5.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

6.

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.

Neuro Oncol. 2014 Dec;16(12):1630-8. doi: 10.1093/neuonc/nou138. Epub 2014 Jul 15.

7.

Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.

Gömöri E, Pál J, Kovács B, Dóczi T.

Diagn Pathol. 2012 Jan 20;7:8. doi: 10.1186/1746-1596-7-8.

8.

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T.

Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

PMID:
20232102
9.

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.

Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M.

Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1.

10.

The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.

Cecener G, Tunca B, Egeli U, Bekar A, Tezcan G, Erturk E, Bayram N, Tolunay S.

Cell Mol Neurobiol. 2012 Mar;32(2):237-44. doi: 10.1007/s10571-011-9753-7. Epub 2011 Sep 18.

PMID:
21928112
11.

High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.

Piperi C, Themistocleous MS, Papavassiliou GA, Farmaki E, Levidou G, Korkolopoulou P, Adamopoulos C, Papavassiliou AG.

Mol Med. 2010 Jan-Feb;16(1-2):1-9. doi: 10.2119/molmed.2009.00140. Epub 2009 Oct 12.

12.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME.

Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Erratum in: Acta Neuropathol. 2013 Jul;126(1):159.

13.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

14.

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.

Neurology. 2013 Oct 22;81(17):1515-22. doi: 10.1212/WNL.0b013e3182a95680. Epub 2013 Sep 25.

PMID:
24068788
15.

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.

Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK.

Clinics (Sao Paulo). 2011;66(10):1747-55.

16.

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.

Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC.

Clin Cancer Res. 2009 Nov 1;15(21):6683-93. doi: 10.1158/1078-0432.CCR-08-2801. Epub 2009 Oct 27.

17.

Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.

Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T.

Med Oncol. 2012 Jun;29(2):1292-6. doi: 10.1007/s12032-011-9901-4. Epub 2011 Mar 11.

PMID:
21394635
18.

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.

Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K.

Acta Neuropathol. 2011 May;121(5):651-61. doi: 10.1007/s00401-011-0803-5. Epub 2011 Feb 3.

PMID:
21287394
19.

[Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].

Kamoshima Y, Motegi H, Terasaka S, Kobayashi H, Yamaguchi S, Murata J, Tanaka S, Houkin K.

No Shinkei Geka. 2012 Feb;40(2):129-35. Japanese.

PMID:
22281465
20.

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.

J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.

Supplemental Content

Support Center